Third, the use of drugs that may be effective for HF, such as SGLT2 inhibitors and GLP-1 receptor agonists, and the use of such drugs was underrepresented in the study cohort because recruitment to the ACCORD study ended in 2005. The gene discussed is GLP1R; the disease is hydrops fetalis.